Table 1 Summary of demographic data and findings of the included studies in the meta-analysis
Study | Study design | Age (year) | No. of participants | Treatment | Dose (mg) | Duration (weeks) | Depression scale | AD duration (year) | Treatment effect | |
|---|---|---|---|---|---|---|---|---|---|---|
Placebo/before | Treatment/after | |||||||||
An et al., 2017 [18] | RCT | 74.33 ± 7.47 | 33 | 27 | Escitalopram | 5–15 | 12 | CSDD | - | No effect |
Banerjee et al., 2011 [27] | RCT | 80 ± 8.4 | 111 | 107 | Sertraline | 50–150 | 13 | CSDD | - | No effect |
Choe et al., 2016 [19] | RCT | 74.33 ± 7.12 | 29 | 28 | Escitalopram | 20 | 52 | CSDD | - | + |
Katona et al., 1998 [28] | RCT | 76.6 | 99 | 99 | Paroxetine | 20–40 | 8 | MADRS | - | + |
Lyketsos et al., 2003 [20] | RCT | 75.5 ± 9.5 | 20 | 24 | Sertraline | 95 | 12 | CSDD, HDRS | 34.6 ± 21.4 | + |
Magai et al., 2000 [29] | RCT | 88.4 ± 6.1 | 14 | 17 | Sertraline | 25–100 | 8 | CSDD, GS | - | No effect |
Mokhber et al., 2014 [21] | RCT | 67.3 ± 3.0 | 20 | 20 | Sertraline | 150 | 12 | HDRS | - | + |
Mowla et al., 2007 [30] | RCT | 69.2 | 41 | 40 | Fluoxetine | 20 | 12 | HDRS | - | No effect |
Munro et al., 2004 [31] | RCT | 75.5 ± 9.7 | 18 | 23 | Sertraline | 25–150 | 12 | CSDD, HDRS | - | + |
Nyth and Gottfries, 1990 [32] | RCT | 77.2 | 29 | 26 | Citalopram | 20 | 16 | MADRS | - | + |
Petracca et al., 2001 [22] | RCT | 70.2 ± 6.3 | 24 | 17 | Fluoxetine | 10–40 | 6 | HDRS | - | No effect |
Rao et al., 2006 [34] | Before/After | 50–90 | 15 | 15 | Escitalopram | 10–20 | 8 | CSDD | - | + |
Rosenberg et al., 2010 [9] | RCT | 77.3 ± 8.0 | 64 | 67 | Sertraline | 50–100 | 12 | CSDD | - | No effect |
Takemoto et al., 2020 a [2] | RCT with before/after design | 73.0 ± 7.3 | 11 | 11 | Sertraline | 31.8 | 12 | HDRS | - | No effect |
Takemoto et al., 2020 b [2] | RCT with before/after design | 79.1 ± 6.1 | 13 | 13 | Escitalopram | 7.3 | 12 | GDS | - | + |
Taragano et al., 1997 [33] | RCT | 71.7 ± 5.0 | 18 | 18 | Fluoxetine | 10 | 6 | HDRS | - | + |